Cellular Biomedicine Group To Present At BIT's 7th Annual World Congress Of Regenerative Medicine & Stem Cells
PALO ALTO, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that Dr. William (Wei) Cao, Chief Executive Officer of the Company, will present "Preclinical and Clinical Results of Mesenchymal Progenitor Cell Treatment for Knee Osteoarthritis" at the 7th Annual World Congress of Regenerative Medicine & Stem Cells (RMSC-2014).
The conference will be held in Haikou, China from November 13-16, 2014 and will feature cellular and regenerative medicine company executives and professors from around the world. The conference theme, "Translations from Concepts to Market", will offer a platform for scientific exchange among all the disciplines involved in the regenerative medicine and stem cell industries.
Dr. Cao will present his speech on November 14 at 8:35am. In addition, he will chair that morning's plenary session entitled "Milestones in Stem Cell and Tissue Engineering Research".
"This is an excellent opportunity for us to meet with other key opinion leaders within the regenerative medicine and stem cell industry and broaden awareness of our Company's proprietary technologies, especially in anticipation of the twelve-month data from our Phase I/IIa clinical trial for knee osteoarthritis (KOA), which we plan to release later in the year," commented Dr. Cao.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.CONTACT: Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 firstname.lastname@example.org Vivian Chen Managing Director Investor Relations, Grayling +1 646 284-9427 email@example.com
Help employers find you! Check out all the jobs and post your resume.